Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know.
Journal
Journal of computer assisted tomography
ISSN: 1532-3145
Titre abrégé: J Comput Assist Tomogr
Pays: United States
ID NLM: 7703942
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Neuroendocrine neoplasms (NENs) are a diverse group of tumors that express neuroendocrine markers and primarily affect the lungs and digestive system. The incidence of NENs has increased over time due to advancements in imaging and diagnostic techniques. Effective management of NENs requires a multidisciplinary approach, considering factors such as tumor location, grade, stage, symptoms, and imaging findings. Treatment strategies vary depending on the specific subtype of NEN. In this review, we will focus on treatment strategies and therapies including the information relevant to clinicians in order to undertake optimal management and treatment decisions, the implications of different therapies on imaging, and how to ascertain their possible complications and treatment effects.
Identifiants
pubmed: 38626751
doi: 10.1097/RCT.0000000000001619
pii: 00004728-990000000-00310
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–860.
Shah S, Gosain R, Groman A, et al. Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States. Cancers (Basel). 2021;13:1753.
Rizen EN, Phan AT. Neuroendocrine tumors: a relevant clinical update. Curr Oncol Rep. 2022;24:703–714.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
Galgano SJ, Iravani A, Bodei L, et al. Imaging of neuroendocrine neoplasms: monitoring treatment response—AJR Expert Panel Narrative Review. Am J Roentgenol. 2022;218:767–780.
Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. Surg Oncol Clin N Am. 2020;29:223–241.
Ramachandran A, Madhusudhan KS. Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol. 2022;28:3008–3026.
Xu Z, Wang L, Dai S, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4:e2124750.
Fernandes CJ, Leung G, Eads JR, et al. Gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2022;51:625–647.
Russo A, Gangi A. The evolving landscape of neuroendocrine tumors. Surg Oncol Clin N Am. 2023;32:185–198.
Garcia-Carbonero R, Rinke A, Valle JW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: systemic therapy - chemotherapy. Neuroendocrinology. 2017;105:281–294.
Panzuto F, Rinzivillo M, Spada F, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas. 2017;46:302–305.
Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–232.
Frizziero M, Spada F, Lamarca A, et al. Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas. Neuroendocrinology. 2019;109:100–112.
Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:1033–1038.
Patel SP, Othus M, Chae YK, et al. A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res. 2020;26:2290–2296.
Mohamed A, Vijayvergia N, Kurian M, et al. Exploring real world outcomes with nivolumab plus ipilimumab in patients with metastatic extra-pulmonary neuroendocrine carcinoma (EP-NEC). Cancers (Basel). 2022;14:2695.
Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35:e13249.
Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–1601.
Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105:212–244.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59:66–74.
Yu R, Wachsman A. Imaging of neuroendocrine tumors. Endocrinol Metab Clin North Am. 2017;46:795–814.
Skoura E, Michopoulou S, Mohmaduvesh M, et al. The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med. 2016;57:34–40.
Fendler WP, Barrio M, Spick C, et al. 68 Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med. 2017;58:307–311.
Hope TA, Calais J, Zhang L, et al. 111 In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med. 2019;60:1266–1269.
Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with Radiolabelled somatostatin analogues. Neuroendocrinology. 2017;105:295–309.
Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.
Mitjavila M, Jimenez-Fonseca P, Belló P, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50:2486–2500.
Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435–e446.
Malczewska A, Kidd M, Matar S, et al. An assessment of circulating chromogranin a as a biomarker of bronchopulmonary neuroendocrine neoplasia: a systematic review and meta-analysis. Neuroendocrinology. 2020;110(3–4):198–216.
Oberg K, Couvelard A, Delle Fave G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2017;105:201–211.
Fairweather M, Swanson R, Wang J, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319–2325.
Al-Toubah T, Morse B, Pelle E, et al. Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide. Oncologist. 2021;26:115–119.
Ferrarotto R, Testa L, Riechelmann RP, et al. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare Tumors. 2013;5:e35.
Lamberti G, Prinzi N, Bongiovanni A, et al. Targeted genomic profiling and chemotherapy outcomes in grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET). Diagnostics (Basel). 2023;13:1595.
Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45:262–277.
Zhang J, Kulkarni HR, Singh A, et al. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60:377–385.
Apostolidis L, Dal Buono A, Merola E, et al. Multicenter analysis of treatment outcomes for systemic therapy in well differentiated grade 3 neuroendocrine tumors (NET G3). Cancers (Basel). 2021;13:1936.
Triponez F, Sadowski SM, Pattou F, et al. Long-term follow-up of MEN1 patients who do not have initial surgery for small ≤2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study. Ann Surg. 2018;268:158–164.
Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:863–881.
Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20:3049.
Michael M, Garcia-Carbonero R, Weber MM, et al. The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review. Oncologist. 2017;22:272–285.
Costa F, Gumz B. Octreotide – a review of its use in treating neuroendocrine tumours. Eur Endocrinol. 2014;10:70–74.
Ryan P, McBride A, Ray D, et al. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: an observational time and motion analysis. J Oncol Pharm Pract. 2019;25:1425–1433.
Pavel M, Ćwikła JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403–414.
Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012;5:161–168.
Cherk MH, Kong G, Hicks RJ, et al. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long-acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging. 2018;18:3.
Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass. Nucl Med Biol. 2010;37:265–275.
Gålne A, Almquist H, Almquist M, et al. A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med. 2019;60:1717–1723.
Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother. 2018;19:909–928.
Pusceddu S, De Braud F, Lo Russo G, et al. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget. 2016;7:44841–44847.
Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28:339–343.
Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:1489–1499.
Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637–642.
Chandrasekharan C. Medical management of gastroenteropancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2020;29:293–316.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
de Mestier L, Dromain C, d'Assignies G, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21:R105–R120.
Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–e21.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759.
Lamarca A, Clouston H, Barriuso J, et al. Follow-up recommendations after curative resection of well-differentiated neuroendocrine tumours: review of current evidence and clinical practice. J Clin Med. 2019;8:1630.
Dromain C, Sundin A, Najran P, et al. Tumor growth rate to predict the outcome of patients with neuroendocrine tumors: performance and sources of variability. Neuroendocrinology. 2021;111:831–839.
van Treijen MJC, Schoevers JMH, Heeres BC, et al. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST? Abdom Radiol (NY). 2022;47:1071–1081.
Öberg K. Future aspects of somatostatin- receptor-mediated therapy. Neuroendocrinology. 2004;80(suppl 1):57–61.
Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - Polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020;47:922–933.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–2584.
Strosberg Jonathan R, Caplin Martyn E, Kunz Pamela L, et al. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol. Published online. 2021;4112–4112.
van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46:704–717.
Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40:2818–2829.
Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–2010.
Kashyap R, Hofman MS, Michael M, et al. Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42:176–185.
Delpassand ES, Tworowska I, Esfandiari R, et al. Targeted α-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial. J Nucl Med. 2022;63:1326–1333.
Ballal S, Yadav MP, Bal C, et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934–946.
Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313–318.
Ortega C, Wong RKS, Schaefferkoetter J, et al. Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE. J Nucl Med. 2021;62:1406–1414.
Camus B, Cottereau AS, Palmieri LJ, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J Clin Med. 2021;10:1267.
Ezziddin S, Adler L, Sabet A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260–1266.
Brabander T, van der Zwan WA, Teunissen JJM, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Endocr Relat Cancer. 2017;24:243–251.
de Baere T, Deschamps F, Tselikas L, et al. GEP-NETS UPDATE: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172:R151–R166.
Steward MJ, Warbey VS, Malhotra A, et al. Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics. 2008;28:1131–1145.
de Baère T, Roche A, Amenabar JM, et al. Liver abscess formation after local treatment of liver tumors. Hepatology. 1996;23:1436–1440.
Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal Cancer: a literature review. Gut Liver. 2013;7:1–6.
Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist. 2019;24:e990–e1005.
Sahu S, Schernthaner R, Ardon R, et al. Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival? Radiology. 2017;283:883–894.
Chapiro J, Duran R, Lin M, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015;25:1993–2003.
Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol. 2000;175:699–704.
Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:052–060.
Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. Am J Roentgenol. 2008;190:67–73.
Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, et al. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013;266:502–513.
Bester L, Hobbins PG, Wang S, et al. Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer. J Med Imaging Radiat Oncol. 2011;55:111–118.
Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. Am J Roentgenol. 2007;188:776–783.
Spina JC, Hume I, Pelaez A, et al. Expected and unexpected imaging findings after 90Y transarterial radioembolization for liver tumors. Radiographics. 2019;39:578–595.